Guardant Health unveils new cancer risk test

PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a pioneer in precision oncology with a market capitalization of $5 billion, has announced the release of its Guardant Hereditary Cancer test. This blood-based germline panel test is designed to identify genetic variants that increase the risk of developing cancer, aiding healthcare providers in making informed treatment decisions and assessing the risk of secondary cancers in patients. According to InvestingPro data, the company maintains strong revenue growth of 28.2% and a healthy gross profit margin of 61.34%.

The test is recommended for patients with a personal or family history of hereditary cancer, as it can guide treatment plans and care decisions, as well as help identify other family members who may be at increased risk. It analyzes 82 genes and can detect genetic variants associated with over 12 types of tumors, including breast, colorectal, and prostate cancers. With a current ratio of 4.11, InvestingPro analysis shows the company maintains strong liquidity to support its product development initiatives.

Guardant Health’s chairman and co-CEO, Helmy Eltoukhy, stated that the introduction of the Guardant Hereditary Cancer test is a significant step towards their mission of conquering cancer with data. It is part of Guardant Health’s broader portfolio aimed at supporting healthcare providers throughout the continuum of cancer care. The test requires only a simple blood draw and results are available within two to three weeks.

Physicians may order this test to develop more personalized treatment plans for patients, reduce risk, and improve outcomes. It can be requested as a standalone test or in conjunction with Guardant360 liquid biopsy tests, without the need for an additional sample.

Guardant Health was founded in 2012 and is dedicated to transforming patient care and accelerating new cancer therapies through its advanced blood and tissue tests, real-world data, and AI analytics. These tests contribute to improved outcomes across all stages of care, from early cancer screening to monitoring for recurrence and treatment selection for advanced cancer. The company’s stock has shown strong momentum, with a 62.45% return over the past year. Eight analysts have recently revised their earnings estimates upward, suggesting growing confidence in the company’s prospects. For comprehensive analysis and additional insights, investors can access the detailed Pro Research Report available on InvestingPro.

The company’s press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations and could differ materially from anticipated results. While analyst price targets range from $47 to $70, Guardant Health cautions that the forward-looking statements should not be relied upon beyond the date of the press release.

This news article is based on a press release statement from Guardant Health, Inc.

In other recent news, Guardant Health has reported first-quarter 2025 earnings that exceeded expectations, with an earnings per share (EPS) of -$0.49, surpassing the forecasted -$0.75. The company also reported a significant revenue increase to $203.5 million, beating the anticipated $190.01 million. This strong financial performance has led Guardant Health to raise its full-year 2025 revenue guidance to a range of $880-$890 million. Analysts have responded positively to these developments, with Scotiabank raising the stock target to $57 and Canaccord Genuity increasing it to $65, both maintaining favorable ratings.

Guardant Health’s growth is attributed to the success of its Shield test and overall product line enhancements. The Shield test, in particular, has seen revenue and volume forecasts increase due to its Advanced Diagnostic Laboratory Test (ADLT) status. The company is also focusing on expanding its commercial infrastructure and reinvesting in its business, which is expected to contribute to its long-term goal of reaching cash flow breakeven by 2028. Additionally, Guardant Health is advancing its product offerings, including the launch of the Guardant360 Tissue test, which requires less tissue and enhances multi-omic testing capabilities.

The company’s strategic moves and product innovations have garnered attention from analysts, who see potential for continued growth and market recognition. Despite a near-term cash burn, analysts like those from Canaccord Genuity believe Guardant Health’s stock is undervalued, emphasizing the company’s contributions to oncology diagnostics. As Guardant Health continues to expand its product portfolio and improve its operational efficiency, it remains a company to watch in the healthcare sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.